Moreover, denosumab, the first fully human monoclonal antibody against RANKL that mimics the endogenous effect of OPG, was shown to be effective in reducing skeletal morbidity rate in breast and prostate cancer (23–26) and found to be more effective in delaying the time to first SREs and reducing the risk of first and subsequent SREs compared to zoledronic acid (27–29). Here, TNFRSF11B is linked to prostate cancer.